Aripiprazole Tablet
Product Images NDC 70518-2897

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The X-axis represents days from randomization, and the Y-axis shows the proportion relapsed. The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier survival curve chart displaying the proportion of subjects with relapse over days from randomization. Two lines compare Aripiprazole (solid blue line) and placebo (dashed red line) groups. The x-axis shows days from 0 to 364, and the y-axis shows the proportion with relapse from 0.0 to 1.0. The number of subjects at risk for both groups is listed below the x-axis across time points.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing the fold change and 90% confidence interval in levels of Dehydro-Aripiprazole with various inhibitors and drugs. The x-axis represents the change relative to a reference without interacting drug, and the y-axis lists CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). Data points for AUC and Cmax are shown for each drug interaction.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A chart titled 'Fold Change and 90% CI' showing the pharmacokinetic impact of various drugs and enzymes relative to a reference without interacting drug. The x-axis represents change relative to reference values, ranging from 0.5 to 3.0, with data points for PK parameters including DMVDRP, AUC, Cmax, and INR for different drugs such as dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI,' displaying the fold change in exposure (AUC, Cmax) relative to reference across various factors including CYP2D6 metabolizer status, gender, age groups, hepatic and renal impairment. The horizontal axis shows change relative to reference, ranging from 0.5 to 3.0, with data points and confidence intervals indicated by horizontal lines for each comparison.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot illustrating the fold change and 90% confidence intervals of Dehydro-Aripiprazole pharmacokinetics variables AUC and Cmax relative to a reference. The chart compares these changes across several factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and renal impairment severity.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart showing the fold change and 90% confidence intervals of aripiprazole levels when co-administered with various inhibitors, inducers, and other drugs. The x-axis represents change relative to a reference without interacting drug. Data points for AUC and Cmax values are plotted for ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole 5 mg tablet packaging label showing a quantity of 30 tablets. The label includes the proprietary and generic name Aripiprazole, the dosage strength of 5 mg, and states Rx only. It features information about repackaging by RemedyRepack Inc. and manufacturer details for Ascend Labs, LLC, Montvale, NJ. The label also includes storage directions and a QR code.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of the active ingredient Aripiprazole, showing its molecular framework including two chlorine atoms, a piperazine ring, an ether linkage, and a quinolinone moiety.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole and Placebo groups. The X-axis represents days from randomization, and the Y-axis shows the proportion with relapse. A table below the graph lists the number of subjects at risk over time for both groups. The Aripiprazole group is represented by a solid blue line, and the Placebo group by a dashed red line.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.